Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2020; 26(40): 6250-6259
Published online Oct 28, 2020. doi: 10.3748/wjg.v26.i40.6250
Novel endoscopic papillectomy for reducing postoperative adverse events (with videos)
Lei Jiang, En-Qiang Ling-Hu, Ning-Li Chai, Wen Li, Feng-Chun Cai, Ming-Yang Li, Xu Guo, Jiang-Yun Meng, Xiang-Dong Wang, Ping Tang, Jing Zhu, Hong Du, Hong-Bin Wang
Lei Jiang, En-Qiang Ling-Hu, Ning-Li Chai, School of Medicine, Nankai University, Tianjin 300071, China
En-Qiang Ling-Hu, Ning-Li Chai, Wen Li, Feng-Chun Cai, Ming-Yang Li, Xu Guo, Jiang-Yun Meng, Xiang-Dong Wang, Ping Tang, Jing Zhu, Hong Du, Hong-Bin Wang, Department of Gastroenterology and Hepatology, Chinese People's Liberation Army General Hospital, Beijing 100853, China
Author contributions: Ling-Hu EQ contributed to study conception and design; Jiang L, Ling-Hu EQ, and Chai NL should be considered as joint first authors; Ling-Hu EQ, Chai NL, Li W, Cai FC, Li MY, and Guo X performed the operations; Meng JY, Wang XD, Tang P, Zhu J, Du H, and Wang HB assisted in operations; Jiang L contributed to data acquisition, analysis, and interpretation and drafted the manuscript; Ling-Hu EQ critically revised the article for important intellectual content; all authors read and approved the manuscript.
Supported by National Key R and D Program of China, No. 2016YFC1303601.
Institutional review board statement: No specific IRB approval was required for this study according to the Ethics Committee of Chinese PLA General Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: Nothing to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: En-Qiang Ling-Hu, MD, PhD, Chief Doctor, Chief Physician, Director, Professor, Department of Gastroenterology and Hepatology, Chinese People's Liberation Army General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. linghuenqiang@vip.sina.com
Received: May 14, 2020
Peer-review started: May 14, 2020
First decision: May 21, 2020
Revised: September 4, 2020
Accepted: September 17, 2020
Article in press: September 17, 2020
Published online: October 28, 2020
Processing time: 166 Days and 8.7 Hours
ARTICLE HIGHLIGHTS
Research background

Endoscopic papillectomy (EP) is one of the main treatments for duodenal papillary lesions.

Research motivation

The postoperative adverse events of EP limit its wide application.

Research objectives

To reduce postoperative adverse events by a novel EP, and to verify its safety and feasibility.

Research methods

The novel method of endoscopic papillectomy mainly includes two modifications: Isolating bile from pancreatic juice with a bile duct stent and closing the wound surface with metal clips and fibrin glue. We retrospectively compared the postoperative condition and adverse event rates of the novel EP and conventional EP to reveal the safety and feasibility of the novel EP.

Research results

Patients who underwent the novel EP had a better postoperative condition and lower adverse event rates compared with patients who underwent the conventional EP. Postoperative perforation was entirely prevented by the novel method.

Research conclusions

This study demonstrates that novel endoscopic papillectomy is a potentially effective and safe method for reducing postoperative adverse events.

Research perspectives

A randomized controlled prospective study is required to further verify the safety and feasibility of the novel EP. After the confirmation, it could be recommended for wider application.